ALTE21C1: Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors
ALTE21C1: Cardiac MRI
What is the goal of the study?
This is a COG sponsored study that has obtained supplemental funding from DoD. It proposes to reapproach AHOD1331 pts with initial banked samples available at COG biobank to examine development of CHIP over time (1yr) and association with cardiac health (as measured by cMRI). 0 GOALS AND OBJECTIVES (SCIENTIFIC AIMS) 1.1 Primary Aims 1.1.1 To assess the prevalence of participants in AHOD1331 with therapy-related clonal hematopoiesis (t-CH) possessing somatic mutations associated with cardiovascular disease (CVD) which are detected after Hodgkin Lymphoma therapy. 1.1.2 To assess participants of AHOD1331 with t-CH for the presence or absence of objective signs of CVD using cardiac MRI. 1.2 Secondary Aims 1.2.1 To assess whether participants in AHOD1331 with t-CH expand this population over time and possess objective findings of CVD. 1.2.2 To assess whether patients both with and without objective findings of CVD using cardiac MRI possess clinical risk factors for CVD. 1.3 Exploratory Aims 1.3.1 To assess the prevalence of patients receiving mediastinal radiation who have objective findings of CVD using cardiac MRI, that also possess t-CH with mutations associated with CVD. 1.3.2 To assess whether specific patient characteristics and treatment (age, gender, race, dexrazoxane usage, etc.) correlate with a higher incidence of t-CH with mutations associated with CVD. 1.3.3 To assess the effects of t-CH on CVD by considering other factors such as patient
Who can participate in the study?
Please contact the study team listed below to learn more.